First step: new liver disease drug tested for safety in small group

NCT ID NCT06308874

Summary

This was a very early, first-in-human study to see if a single dose of a potential new medicine called J2H-1702 is safe for people. It involved 16 healthy female volunteers to check for side effects and measure how the drug moves through the body. The goal was to gather basic safety information to see if testing can continue in people with the liver disease it is intended to treat.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • J2H Biotech

    Suwon, Gyeonggi-do, 16684, South Korea

Conditions

Explore the condition pages connected to this study.